Abiomed Announces Participation in Three Upcoming Physician Society Meetings: SCAI, HRS, & EuroPCRDANVERS, Mass.
, May 8, 2012
(GLOBE NEWSWIRE) -- Abiomed, Inc.
(Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its participation in three upcoming physician society meetings:
Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12 in Las Vegas, Nevada – Booth 417
Heart Rhythm Society (HRS), May 9-12 in Boston, Massachusetts – Booth 1413
EuroPCR, May 15-18 in Paris, France – Booth M69 (Level 2)
At all three meetings, Abiomed will conduct daily booth demonstrations as well as host hands-on simulations of the Impella® platform. At EuroPCR, Abiomed will begin the early commercial roll-out of Impella cVADTM with European physicians post the Impella cVAD's CE Mark approval last month. Full commercial availability of the Impella cVAD in the European market is expected by summer 2012.
The Impella cVAD is not currently cleared for sale or use in the United States.
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12768
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
CONTACT: Susie Lisa
Senior Director, Investor Relations and Corporate Development